{"protocolSection": {"identificationModule": {"nctId": "NCT00627679", "orgStudyIdInfo": {"id": "MAP0010-CL-P101"}, "organization": {"fullName": "Allergan", "class": "INDUSTRY"}, "briefTitle": "Safety and Blood Level Study of Unit Dose Budesonide", "officialTitle": "A Randomized, Double Blind, Active Controlled, Single Dose, 4 Arm, 4 Period Crossover, Phase 1 Study Investigating the Tolerability and Pharmacokinetics of MAP0010", "acronym": "UDB P101"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-12"}, "primaryCompletionDateStruct": {"date": "2005-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2006-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-02-22", "studyFirstSubmitQcDate": "2008-02-29", "studyFirstPostDateStruct": {"date": "2008-03-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-08-19", "resultsFirstSubmitQcDate": "2013-08-19", "resultsFirstPostDateStruct": {"date": "2013-10-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-12-09", "lastUpdatePostDateStruct": {"date": "2014-01-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Allergan", "class": "INDUSTRY"}, "collaborators": [{"name": "MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan", "class": "INDUSTRY"}, {"name": "Q-Pharm Pty Limited", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules\u00ae (Budesonide) in healthy volunteers."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Pediatric asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 16, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment sequence: A, B, D, C", "type": "EXPERIMENTAL", "description": "Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules\u00ae) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5", "interventionNames": ["Drug: Budesonide Inhalation Suspension", "Drug: MAP0010 low dose", "Drug: MAP0010 intermediate dose", "Drug: MAP0010 high dose"]}, {"label": "Treatment sequence: B, C, A, D", "type": "EXPERIMENTAL", "description": "Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules\u00ae) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5", "interventionNames": ["Drug: Budesonide Inhalation Suspension", "Drug: MAP0010 low dose", "Drug: MAP0010 intermediate dose", "Drug: MAP0010 high dose"]}, {"label": "Treatment sequence: C, D, B, A", "type": "EXPERIMENTAL", "description": "Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules\u00ae) delivered by nebulization at Visit 5", "interventionNames": ["Drug: Budesonide Inhalation Suspension", "Drug: MAP0010 low dose", "Drug: MAP0010 intermediate dose", "Drug: MAP0010 high dose"]}, {"label": "Treatment sequence: D, A, C, B", "type": "EXPERIMENTAL", "description": "Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules\u00ae) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5", "interventionNames": ["Drug: Budesonide Inhalation Suspension", "Drug: MAP0010 low dose", "Drug: MAP0010 intermediate dose", "Drug: MAP0010 high dose"]}], "interventions": [{"type": "DRUG", "name": "Budesonide Inhalation Suspension", "description": "Treatment A = a single dose of Pulmicort Respules\u00ae (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.", "armGroupLabels": ["Treatment sequence: A, B, D, C", "Treatment sequence: B, C, A, D", "Treatment sequence: C, D, B, A", "Treatment sequence: D, A, C, B"], "otherNames": ["Pulmicort Respules\u00ae"]}, {"type": "DRUG", "name": "MAP0010 low dose", "description": "Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.", "armGroupLabels": ["Treatment sequence: A, B, D, C", "Treatment sequence: B, C, A, D", "Treatment sequence: C, D, B, A", "Treatment sequence: D, A, C, B"]}, {"type": "DRUG", "name": "MAP0010 intermediate dose", "description": "Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.", "armGroupLabels": ["Treatment sequence: A, B, D, C", "Treatment sequence: B, C, A, D", "Treatment sequence: C, D, B, A", "Treatment sequence: D, A, C, B"]}, {"type": "DRUG", "name": "MAP0010 high dose", "description": "Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.", "armGroupLabels": ["Treatment sequence: A, B, D, C", "Treatment sequence: B, C, A, D", "Treatment sequence: C, D, B, A", "Treatment sequence: D, A, C, B"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010", "description": "The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).", "timeFrame": "8 hours"}, {"measure": "Tmax of Budesonide After Administration of Pulmicort Respules\u00ae and Three Dose Levels of MAP0010", "description": "Tmax is the time to maximum concentration of a drug in the plasma. The Tmax of budesonide is reported in minutes (min).", "timeFrame": "8 hours"}, {"measure": "AUC(0-8) of Budesonide After Administration of Pulmicort Respules\u00ae and Three Doses of MAP0010", "description": "The AUC(0-8) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-8) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "timeFrame": "8 hours"}, {"measure": "AUC(0-inf) of Budesonide After Administration of Pulmicort Respules\u00ae and Three Dose Levels of MAP0010", "description": "The AUC(0-inf) is the area under the plot of plasma concentration of drug against time to infinity (inf) after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "timeFrame": "8 hours"}, {"measure": "Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules\u00ae and Three Dose Levels of MAP0010", "description": "Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes (min).", "timeFrame": "8 hours"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy adult volunteers, aged 18-50 years\n* BMI less than 30 kg/m2\n* Non smoker (currently and \\<10 pack years total if ex-smoker)\n\nExclusion Criteria:\n\n* Any use of corticosteroid in previous 4 weeks\n* Pregnancy/lactation\n* Significant blood donation (or testing) in previous 8 weeks", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Joanne Marjason, MBBS", "affiliation": "Q-Pharm Pty Limited", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Q-Pharm Pty Limited", "city": "Brisbane", "state": "Queensland", "zip": "QLD 4006", "country": "Australia", "geoPoint": {"lat": -27.46794, "lon": 153.02809}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All subjects received all 4 treatments in a randomly assigned order. The treatments were:\n\nTreatment A: Pulmicort Respules\u00ae Treatment B: MAP0010 low dose Treatment C: MAP0010 intermediate dose Treatment D: MAP0010 high dose The sequences were Treatments ABDC, BACD, CDBA, DACB.", "groups": [{"id": "FG000", "title": "Treatment A, B, D, C", "description": "Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Pulmicort Respules\u00ae delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5"}, {"id": "FG001", "title": "Treatment B, C, A, D", "description": "Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Pulmicort Respules\u00ae delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5"}, {"id": "FG002", "title": "Treatment C, D, B, A", "description": "Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Pulmicort Respules\u00ae delivered by nebulization at Visit 5"}, {"id": "FG003", "title": "Treatment D, A, C, B", "description": "Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Pulmicort Respules\u00ae delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Patients", "description": "All patients that were enrolled in the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "23.3", "spread": "4.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010", "description": "The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "8 hours", "groups": [{"id": "OG000", "title": "Treatment A", "description": "a single dose of Pulmicort Respules\u00ae delivered by nebulization as per protocol"}, {"id": "OG001", "title": "Treatment B", "description": "a single dose of MAP0010 low dose delivered by nebulization as per protocol"}, {"id": "OG002", "title": "Treatment C", "description": "a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol"}, {"id": "OG003", "title": "Treatment D", "description": "a single dose of MAP0010 high dose delivered by nebulization as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "303.5", "spread": "177.4"}, {"groupId": "OG001", "value": "106.2", "spread": "63.47"}, {"groupId": "OG002", "value": "239.9", "spread": "140.1"}, {"groupId": "OG003", "value": "434.5", "spread": "246.9"}]}]}]}, {"type": "PRIMARY", "title": "Tmax of Budesonide After Administration of Pulmicort Respules\u00ae and Three Dose Levels of MAP0010", "description": "Tmax is the time to maximum concentration of a drug in the plasma. The Tmax of budesonide is reported in minutes (min).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "min", "timeFrame": "8 hours", "groups": [{"id": "OG000", "title": "Treatment A", "description": "a single dose of Pulmicort Respules\u00ae delivered by nebulization as per protocol"}, {"id": "OG001", "title": "Treatment B", "description": "a single dose of MAP0010 low dose delivered by nebulization as per protocol"}, {"id": "OG002", "title": "Treatment C", "description": "a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol"}, {"id": "OG003", "title": "Treatment D", "description": "a single dose of MAP0010 high dose delivered by nebulization as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.063", "spread": "7.122"}, {"groupId": "OG001", "value": "4.467", "spread": "3.270"}, {"groupId": "OG002", "value": "3.125", "spread": "1.500"}, {"groupId": "OG003", "value": "3.688", "spread": "1.448"}]}]}]}, {"type": "PRIMARY", "title": "AUC(0-8) of Budesonide After Administration of Pulmicort Respules\u00ae and Three Doses of MAP0010", "description": "The AUC(0-8) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-8) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*min/mL", "timeFrame": "8 hours", "groups": [{"id": "OG000", "title": "Treatment A", "description": "a single dose of Pulmicort Respules\u00ae delivered by nebulization as per protocol"}, {"id": "OG001", "title": "Treatment B", "description": "a single dose of MAP0010 low dose delivered by nebulization as per protocol"}, {"id": "OG002", "title": "Treatment C", "description": "a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol"}, {"id": "OG003", "title": "Treatment D", "description": "a single dose of MAP0010 high dose delivered by nebulization as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29040", "spread": "9316"}, {"groupId": "OG001", "value": "3978", "spread": "1974"}, {"groupId": "OG002", "value": "8626", "spread": "4184"}, {"groupId": "OG003", "value": "22130", "spread": "9675"}]}]}]}, {"type": "PRIMARY", "title": "AUC(0-inf) of Budesonide After Administration of Pulmicort Respules\u00ae and Three Dose Levels of MAP0010", "description": "The AUC(0-inf) is the area under the plot of plasma concentration of drug against time to infinity (inf) after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*min/mL", "timeFrame": "8 hours", "groups": [{"id": "OG000", "title": "Treatment A", "description": "a single dose of Pulmicort Respules\u00ae delivered by nebulization as per protocol"}, {"id": "OG001", "title": "Treatment B", "description": "a single dose of MAP0010 low dose delivered by nebulization as per protocol"}, {"id": "OG002", "title": "Treatment C", "description": "a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol"}, {"id": "OG003", "title": "Treatment D", "description": "a single dose of MAP0010 high dose delivered by nebulization as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31480", "spread": "10690"}, {"groupId": "OG001", "value": "4391", "spread": "1423"}, {"groupId": "OG002", "value": "7842", "spread": "3647"}, {"groupId": "OG003", "value": "25290", "spread": "11750"}]}]}]}, {"type": "PRIMARY", "title": "Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules\u00ae and Three Dose Levels of MAP0010", "description": "Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes (min).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "min", "timeFrame": "8 hours", "groups": [{"id": "OG000", "title": "Treatment A", "description": "a single dose of Pulmicort Respules\u00ae delivered by nebulization as per protocol"}, {"id": "OG001", "title": "Treatment B", "description": "a single dose of MAP0010 low dose delivered by nebulization as per protocol"}, {"id": "OG002", "title": "Treatment C", "description": "a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol"}, {"id": "OG003", "title": "Treatment D", "description": "a single dose of MAP0010 high dose delivered by nebulization as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "145.4", "spread": "40.84"}, {"groupId": "OG001", "value": "73.02", "spread": "33.43"}, {"groupId": "OG002", "value": "78.35", "spread": "27.08"}, {"groupId": "OG003", "value": "140.0", "spread": "54.19"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Treatment A", "description": "a single dose of Pulmicort Respules\u00ae delivered by nebulization as per protocol", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 4, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Treatment B", "description": "a single dose of MAP0010 low dose delivered by nebulization as per protocol", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 4, "otherNumAtRisk": 16}, {"id": "EG002", "title": "Treatment C", "description": "a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 3, "otherNumAtRisk": 16}, {"id": "EG003", "title": "Treatment D", "description": "a single dose of MAP0010 high dose delivered by nebulization as per protocol", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 3, "otherNumAtRisk": 16}], "otherEvents": [{"term": "thrombophlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "hematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "epitaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "pharyngolaryngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "herpes simplex", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "vaginal candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "hordeolum", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "anemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "eye irritation", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (8.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."}, "pointOfContact": {"title": "VP, Scientific Affairs", "organization": "MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan", "email": "dkellerman@mappharma.com", "phone": "(650) 386-3100"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}